本帖最后由 老马 于 2012-1-13 21:20 编辑
9 D4 J2 U+ {* G: s
4 V8 O! w4 \/ O: o爱必妥和阿瓦斯丁的比较1 H1 A+ N& K9 c/ ]3 K
$ |9 [% P' J. }$ {- T0 w
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/1 V; t: s* J. y( {7 }9 h
2 L( Q* ?' b: T/ i% j0 L; T
( L/ Z j# k( e, W9 \1 l
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
7 s; `5 j& L8 k2 _3 V2 d==================================================
" d5 s U( v# t6 H6 lOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
& ?1 y) H+ u* r+ J9 l2 ?5 KPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
0 P4 b8 o* e+ q6 { n+ WResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.) ?# i/ }- V2 o
|